WEST Search History

DATE: Monday, November 25, 2002

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
L2	dual specificity phosphatase same humen and (nucleic acid or gene or dna or cdna)	40	L2
L1	duel specificity phosphatase same humen and (nucleic acid or gene or dna or cdna)	0	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 20 of 40 returned.

☐ 1. Document ID: US 20020155505 A1

L2: Entry 1 of 40 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155505
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155505 A1

TITLE: Methods for ligand discovery

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wells, Jim	Burlingame	CA	US	
Erlanson, Dan	San Francisco	CA	US	
Braisted, Andrew C.	San Francisco	CA	US	

US-CL-CURRENT: 435/7.1; 530/324, 564/161, 564/192, 564/30, 564/84

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20020151007 A1

L2: Entry 2 of 40 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151007
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151007 A1

TITLE: Methods of use of a novel lysyl oxidase-related protein

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Khodadoust, Mehran M.	Brookline	MA	US	
MacBeth, Kyle J.	Boston	MA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 20020150954 A1

L2: Entry 3 of 40 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150954
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150954 A1

TITLE: Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Durden, Donald L.	Indianapolis	IN	US	

US-CL-CURRENT: 435/7.23; 514/12, 514/152, 514/27, 514/283, 514/449

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20020137170 A1

L2: Entry 4 of 40 File: PGPB Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137170
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137170 A1

TITLE: DSP-16 dual-specificity phosphatase

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20020123464 A1

L2: Entry 5 of 40 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123464
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020123464 A1

TITLE: 69087, 15821, and 15418, methods and compositions of human proteins and uses thereof

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kapeller-Libermann, Rosana	Chestnut Hill	MA	US	
Bandaru, Rajasekhar	Watertown	MA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 6. Document ID: US 20020102693 A1

L2: Entry 6 of 40 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102693 A1

TITLE: DSP-14 dual-specificity phosphatase

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 7. Document ID: US 20020102691 A1

L2: Entry 7 of 40 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102691
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102691 A1

TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Davis, Roger J.	Princeton	MA	US	
Raingeaud, Joel	Palaiseau		FR	
Derijard, Benoit	Nice		FR	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 8. Document ID: US 20020094561 A1

L2: Entry 8 of 40 File: PGPB Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094561
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094561 A1

TITLE: Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ye, Jane	Boyds	MD	US	
Yan, Chunhua	Boyds	MD	US	
Di Francesco, Valentina	Rockville	MD	US	
Beasley, Ellen M.	Darnestown	MD	US	

US-CL-CURRENT: 435/196; 435/325, 435/6, 435/69.1, 435/7.1, 536/23.2, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 9. Document ID: US 20020090703 A1

L2: Entry 9 of 40 File: PGPB Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090703
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020090703 A1

TITLE: Mammalian protein phosphatases

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Plowman, Gregory D.	San Carlos	CA	US	
Martinez, Ricardo	Foster City	CA	US	
Whyte, David	Belmont	CA	US	
Manning, Gerard	Menlo Park	CA	US	
Sudarsanam, Sucha	Greenbrae	CA	US	
Caenepeel, Sean	Oakland	CA	US	
Hill, Ron	Burlingame	CA	US	
Flanagan, Peter	San Francisco	CA	US	

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 10. Document ID: US 20020090624 A1

L2: Entry 10 of 40 File: PGPB Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090624
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020090624 A1

TITLE: Gene markers useful for detecting skin damage in response to ultraviolet radiation

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Blumenberg, Miroslav	New York	NY	US	

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 11. Document ID: US 20020081612 A1

L2: Entry 11 of 40 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081612
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081612 A1

TITLE: Detection and diagnosis of smoking related cancers

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Katz, Ruth	Houston	TX	US	
Jiang, Feng	Houston	TX	US	

US-CL-CURRENT: 435/6; 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 12. Document ID: US 20020068287 A1

L2: Entry 12 of 40 File: PGPB Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068287
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068287 A1

TITLE: Methods of identifying integrin ligands using differential gene expression

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fougerolles, Antonin de	Brookline	MA	US	
Carulli, John	Southborough	MA	US	
Kotelianski, Victor	Boston	MA	US	
Green, Cynthia D.	Madison	CT	US	
Hsu, Andro	Berkley	CA	US	

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 13. Document ID: US 20020065406 A1

L2: Entry 13 of 40 File: PGPB May 30, 2002

PGPUB-DOCUMENT-NUMBER: 20020065406
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020065406 A1

TITLE: 18221, a novel dual specificity phosphatase and uses thereof

PUBLICATION-DATE: May 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel A.	Newton	MA	US	

US-CL-CURRENT: 536/23.1; 435/196, 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 14. Document ID: US 20020034807 A1

L2: Entry 14 of 40 File: PGPB Mar 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020034807
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020034807 A1

TITLE: 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor

PUBLICATION-DATE: March 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel A.	Newton	MA	US	

US-CL-CURRENT: 435/196; 435/325, 435/6, 435/69.1, 435/7.1, 514/44, 530/388.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 15. Document ID: US 20020009797 A1

L2: Entry 15 of 40 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009797
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009797 A1

TITLE: Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolf, David A.	Houston	TX	US	
Goodwin, Thomas J.	Friendswood	TX	US	

US-CL-CURRENT: 435/289.1; 435/173.8, 435/298.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 16. Document ID: US 20020009730 A1

L2: Entry 16 of 40 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009730
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009730 A1

TITLE: Human stress array

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenchik, Alex	Palo Alto	CA	US	
Lukashev, Matvey E.	Newton	MA	US	

US-CL-CURRENT: 435/6; 536/24.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 17. Document ID: US 20010049358 A1

L2: Entry 17 of 40 File: PGPB Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010049358
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010049358 A1

TITLE: DSP-12 and DSP-13 dual-specificity phosphatases

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 514/12; 435/196, 435/325, 435/6, 435/69.1, 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 18. Document ID: US 6436685 B1

L2: Entry 18 of 40 File: USPT Aug 20, 2002

US-PAT-NO: 6436685
DOCUMENT-IDENTIFIER: US 6436685 B1

TITLE: CSAPTP protein molecules and uses therefor

DATE-ISSUED: August 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan L.	Lexington	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/254.11, 435/320.1, 435/6, 536/23.2

ABSTRACT:

The invention provides isolated nucleic acid molecules, designated CSAPTP nucleic acid molecules, which encode novel protein tyrosine phosphatases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPTP nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for producing CSAPTP polypeptides.

15 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 19. Document ID: US 6420153 B1

L2: Entry 19 of 40 File: USPT Jul 16, 2002

US-PAT-NO: 6420153
DOCUMENT-IDENTIFIER: US 6420153 B1

TITLE: 18232, a novel dual specificity phosphatase and uses therefor

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Meyers; Rachel A.	Newton	MA		
Weich; Nadine	Brookline	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 536/23.1, 536/23.2, 536/24.1

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 18232 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18232 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18232 gene has been introduced or disrupted. The invention still further provides isolated 18232 proteins, fusion proteins, antigenic peptides and anti-18232 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating the differentiation and proliferation of hematopoietic cells (e.g., erythroid cells) utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing erythroid-associated disorders such as anemias, leukemias, and erythrocytosis are disclosed.

15 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 20. Document ID: US 6335170 B1

L2: Entry 20 of 40 File: USPT Jan 1, 2002

US-PAT-NO: 6335170
DOCUMENT-IDENTIFIER: US 6335170 B1

TITLE: Gene expression in bladder tumors

DATE-ISSUED: January 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Orntoft; Torben F.	DK 8230 Aabyhoj			DK

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

ABSTRACT:

Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

21 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
dual specificity phosphatase same humen and (nucleic acid or gene or dna or cdna)	40

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 21 through 40 of 40 returned.

☐ 21. Document ID: US 6331614 B1

L2: Entry 21 of 40 File: USPT Dec 18, 2001

US-PAT-NO: 6331614
DOCUMENT-IDENTIFIER: US 6331614 B1

TITLE: Human CDC14A gene

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wong; Alexander K. C.	La Jolla	CA		
Teng; David H. -F.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 536/23.1

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to human CDC14A gene which has been found to be mutated in certain tumor cell lines. More specifically, the invention relates to a novel sequence for the human CDC14A gene. The present invention further relates to somatic mutations in the CDC14A gene in human cancer and their use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the CDC14A gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the CDC14A gene for mutations, which are useful for diagnosing the predisposition to cancer.

14 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 22. Document ID: US 6331396 B1

L2: Entry 22 of 40 File: USPT Dec 18, 2001

US-PAT-NO: 6331396
DOCUMENT-IDENTIFIER: US 6331396 B1

TITLE: Arrays for identifying agents which mimic or inhibit the activity of interferons

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Silverman; Robert H.	Beachwood	OH		
Williams; Bryan R. G.	Cleveland	OH		
Der; Sandy	Cleveland	OH		

US-CL-CURRENT: 435/6; 435/287.2, 536/23.1, 536/23.52, 536/24.3, 536/24.31

ABSTRACT:

Methods and model systems for identifying and characterizing new therapeutic agents, particularly proteins, which mimic or inhibit the activity of all interferons, Type I interferons, IFN-.alpha., IFN-.beta., or IFN-.gamma.. The method comprises administering an interferon selected from the group consisting of IFN-.alpha., IFN .beta., IFN-.tau., IFN-.omega., IFN-.gamma., and combinations thereof to cultured cells, administering the candidate agent to a duplicate culture of cells; and measuring the effect of the candidate agent and the interferon on the transcription or translation of one or, preferably, a plurality of the interferon stimulated genes or the interferon repressed genes (hereinafter referred to as "ISG's" and "IRGs", respectively). The model system is an array with gene probes that hybridize with from about 100 to about 5000 ISG and IRG transcripts.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 23. Document ID: US 6300092 B1

L2: Entry 23 of 40 File: USPT Oct 9, 2001

US-PAT-NO: 6300092
DOCUMENT-IDENTIFIER: US 6300092 B1

TITLE: Methods of use of a novel lysyl oxidase-related protein

DATE-ISSUED: October 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Khodadoust; Mehran M.	Brookline	MA		
MacBeth; Kyle J.	Boston	MA		

US-CL-CURRENT: 435/16; 435/189, 435/193, 435/25, 435/7.1

ABSTRACT:

Novel Lor-2 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Lor-2 proteins, the invention further provides isolated Lor-2 fusion proteins, antigenic peptides and anti-Lor-2 antibodies. The invention also provides Lor-2 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Lor-2 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

17 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 24. Document ID: US 6268135 B1

L2: Entry 24 of 40 File: USPT Jul 31, 2001

US-PAT-NO: 6268135
DOCUMENT-IDENTIFIER: US 6268135 B1

TITLE: Phospholipase molecule and uses therefor

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan	Lexington	MA		

US-CL-CURRENT: 435/6; 435/198, 435/21, 435/252.3, 435/320.1, 530/350, 536/23.2, 536/23.5

ABSTRACT:

Novel CSAPL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPL proteins, the invention further provides isolated CSAPL fusion proteins, antigenic peptides and anti-CSAPL antibodies. The invention also provides CSAPL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

14 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 25. Document ID: US 6258582 B1

L2: Entry 25 of 40 File: USPT Jul 10, 2001

US-PAT-NO: 6258582
DOCUMENT-IDENTIFIER: US 6258582 B1

TITLE: CSAPTP nucleic acid molecules and uses therefor

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan	Jamaica Plain	MA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/69.1, 530/350, 536/23.2, 536/23.5

ABSTRACT:

Novel CSAPTP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPTP proteins, the invention further provides isolated CSAPTP fusion proteins, antigenic peptides and anti-CSAPTP antibodies. The invention also provides CSAPTP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPTP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

23 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 26. Document ID: US 6174676 B1

L2: Entry 26 of 40 File: USPT Jan 16, 2001

US-PAT-NO: 6174676
DOCUMENT-IDENTIFIER: US 6174676 B1

TITLE: Cytokine-stress- and oncoprotein-activated human protein kinase kinases

DATE-ISSUED: January 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Roger J.	Princeton	MA		
Raingeaud; Joel	Palaiseau			FR
Derijard; Benoit	Nice			FR

US-CL-CURRENT: 435/6; 435/194, 435/810, 435/975, 436/501, 436/94, 530/387.1, 536/23.1, 536/24.3, 536/24.33, 536/25.3

ABSTRACT:

Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human-MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.

29 Claims, 28 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 27. Document ID: US 6162897 A

L2: Entry 27 of 40 File: USPT Dec 19, 2000

US-PAT-NO: 6162897
DOCUMENT-IDENTIFIER: US 6162897 A

TITLE: 17q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: December 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 530/350; 424/174.1, 435/7.1

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

3 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 28. Document ID: US 6136596 A

L2: Entry 28 of 40 File: USPT Oct 24, 2000

US-PAT-NO: 6136596
DOCUMENT-IDENTIFIER: US 6136596 A

TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

DATE-ISSUED: October 24, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Roger J.	Princeton	MA		
Whitmarsh; Alan	Shrewsbury	MA		
Tournier; Cathy	Worcester	MA		

US-CL-CURRENT: 435/325; 435/194, 435/252.3, 435/320.1, 536/23.2

ABSTRACT:

Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.

9 Claims, 54 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 54

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 29. Document ID: US 6074851 A

L2: Entry 29 of 40 File: USPT Jun 13, 2000

US-PAT-NO: 6074851
DOCUMENT-IDENTIFIER: US 6074851 A

TITLE: Catalytic macro molecules having cdc25B like activity

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deibel, Jr.; Martin R.	Kalamazoo	MI		
Yem; Anthony W.	Kalamazoo	MI		
Wolfe; Cindy L.	Portage	MI		

US-CL-CURRENT: 435/69.7; 435/194

ABSTRACT:

This invention discloses novel forms of catalytic macro molecules that are related to cdc25B, a cell cycle specific phosphatase. These special domains of cdc25B, special fusions with GST, and unique peptides and proteins, their utility, and the method of making them are all described.

3 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 30. Document ID: US 5998188 A

L2: Entry 30 of 40 File: USPT Dec 7, 1999

US-PAT-NO: 5998188
DOCUMENT-IDENTIFIER: US 5998188 A

TITLE: Mitogen activated protein kinase phosphatase cDNAS and their biologically active expression products

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stork; Philip J. S.	Portland	OR		
Misra-Press; Anita	Portland	OR		

US-CL-CURRENT: 435/196

ABSTRACT:

The invention relates to a novel mitogen-activated protein kinase phosphatase, MKP-2. The invention further relates to methods and means for preparing and to nucleic acids encoding this protein. The MKP-2 of the present invention is useful in the control of cell growth, differentiation and apoptosis.

3 Claims, 44 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 31. Document ID: US 5804427 A

L2: Entry 31 of 40 File: USPT Sep 8, 1998

US-PAT-NO: 5804427
DOCUMENT-IDENTIFIER: US 5804427 A

TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

DATE-ISSUED: September 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Roger	Princeton	MA		
Raingeaud; Joel	Bazoges en Pareds			FR
Derijard; Benoit	Marseilles			FR

US-CL-CURRENT: 435/194; 435/183, 530/350

ABSTRACT:

Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including

cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.

4 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 32. Document ID: US 5753441 A

L2: Entry 32 of 40 File: USPT May 19, 1998

US-PAT-NO: 5753441
DOCUMENT-IDENTIFIER: US 5753441 A

TITLE: 170-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 435/6; 424/1.11, 435/4, 435/7.1, 435/7.2, 435/7.9, 435/91.1, 435/91.2, 436/500, 436/548, 530/387.2, 530/388.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

37 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 33. Document ID: US 5736381 A

L2: Entry 33 of 40 File: USPT Apr 7, 1998

US-PAT-NO: 5736381
DOCUMENT-IDENTIFIER: US 5736381 A

TITLE: Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

DATE-ISSUED: April 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Roger J.	Princeton	MA	01541	
Gupta; Shashi	Worcester	MA	01604	
Raingeaud; Joel	85390 Bazoges en Pareds			FR
Derijard; Benoit	13012 Marseille			FR

US-CL-CURRENT: 435/252.3; 435/320.1, 435/325, 435/6, 435/69.1, 435/91.1, 536/23.1, 536/23.5, 536/24.31, 536/24.33

ABSTRACT:

Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.

20 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 34. Document ID: US 5710001 A

L2: Entry 34 of 40 File: USPT Jan 20, 1998

US-PAT-NO: 5710001
DOCUMENT-IDENTIFIER: US 5710001 A

TITLE: 17q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT		
Goldgar; David E.	Salt Lake City	UT		
Miki; Yoshio	Salt Lake City	UT		
Swenson; Jeff	Salt Lake City	UT		
Kamb; Alexander	Salt Lake City	UT		
Harshman; Keith D.	Salt Lake City	UT		
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Tavtigian; Sean V.	Salt Lake City	UT		
Wiseman; Roger W.	Durham	NC		
Futreal; P. Andrew	Durham	NC		

US-CL-CURRENT: 435/6; 435/7.1, 435/7.9, 435/91.2, 530/300, 530/350, 530/388.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 35. Document ID: US 5709999 A

L2: Entry 35 of 40 File: USPT Jan 20, 1998

US-PAT-NO: 5709999
DOCUMENT-IDENTIFIER: US 5709999 A

TITLE: Linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shattuck-Eidens; Donna M.	Salt Lake City	UT		
Simard; Jacques	St. Augustin de Desmaures			CA
Durocher; Francine	Ste-Foy			CA
Emi; Mitsuuru	Tokyo			JP
Nakamura; Yusuke	Yokohama			JP

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 36. Document ID: US 5573935 A

L2: Entry 36 of 40 File: USPT Nov 12, 1996

US-PAT-NO: 5573935
DOCUMENT-IDENTIFIER: US 5573935 A

TITLE: Protein tyrosine kinase A6

DATE-ISSUED: November 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beeler; John F.	Bethesda	MD		
Larochelle; William	Gaithersburg	MD		
Aaronson; Stuart A.	Great Falls	VA		

US-CL-CURRENT: 435/194; 435/252.3, 435/252.33, 435/320.1, 435/69.8, 536/23.2, 536/23.5, 930/240

ABSTRACT:

A novel protein tyrosine kinase (A6) exhibiting no significant similarity to any known kinase. This protein in widely expressed throughout the body and is present in a variety of vertebrates. The cDNA was expressed in bacteria as a fusion protein which was both autophosphorylated and exhibited kinase activity toward exogenous substrates. Potential uses of this invention include immunodiagnostics and antiproliferative therapeutics.

10 Claims, 1 Drawing figures
Exemplary Claim Number: 1,9
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 37. Document ID: WO 200231132 A2 AU 200211597 A

L2: Entry 37 of 40 File: DWPI Apr 18, 2002

DERWENT-ACC-NO: 2002-416863
DERWENT-WEEK: 200254

TITLE: Novel human dual specificity phosphatase, 8843 and polynucleotides for identifying modulators for use in treating or preventing an erythroid-associated disorder e.g. anemia or leukemia in a subject

INVENTOR: WEICH, N

PRIORITY-DATA: 2000US-0686673 (October 11, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200231132 A2	April 18, 2002	E	125	C12N009/16
AU 200211597 A	April 22, 2002		000	C12N009/16

INT-CL (IPC): C12 N 9/16; C12 N 15/12

ABSTRACTED-PUB-NO: WO 200231132A
BASIC-ABSTRACT:

NOVELTY - An isolated human dual specificity phosphatase polypeptide (I), 8843, having a sequence (S1) of 201 amino acids (aa) as given in specification, or a sequence encoded by polynucleotide having a sequence of 839 or 606 bp as given in the specification or its complement, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated 8843 nucleic acid (NA) molecule (II) encoding (I);

(2) modulating (M1) erythropoiesis or proliferation, differentiation or survival of CD34 positive cell, by contacting an positive cell with an agent that modulates the activity or expression of (I)/(II), thereby modulates proliferation, differentiation, or survival of the cell; and

(3) treating or preventing (M2) an erythroid-associated disorder in a subject by administering an agent that modulates activity or expression of (I).

ACTIVITY - Antianemia; Cytostatic; Nephrotrophic; Antiarthritic; Antirheumatic; Anti-human immunodeficiency virus (HIV); Dermatological. No supporting data is given.

MECHANISM OF ACTION - Gene therapy; Modulator of (I) or (II).

USE - (I) is useful for identifying a compound modulates the activity of (I). M1 is useful for modulating erythropoiesis in a subject preferably human having an erythroid associated disorder. (I) and (II) are useful for evaluating the efficacy of a treatment of an erythroid associated disorder which is an anemia or leukemia, in a subject; and for diagnosing the disorder by evaluating and comparing expression or activity of (I)/(II). M1 is useful for modulating erythropoiesis or proliferation, differentiation or survival of CD34 positive cell; and M2 is useful for treating or preventing an erythroid-associated disorder in a subject (claimed). The modulator thus identified is also useful for treating chronic renal failure, malignancies, adult and juvenile rheumatoid arthritis, disorders of hemoglobin synthesis, prematurity and zidovudine treatment of HIV infection; and disorders of liver e.g. jaundice, kidney e.g. Heymann nephritis, lung e.g. congenital anomalies and skin (dermal) e.g. seborrheic keratoses. (I) is useful for producing antibodies, in drug screening assays, in competition

binding assays to discover compounds that interact with the protein, in pharmacogenomic analysis and for monitoring therapeutic effects during clinical trials and other treatment. (IV) is useful for isolating (I), to assess abnormal tissue distribution or abnormal expression during development, to identify protein turnover, to assess normal and aberrant subcellular localization of cells in various tissues in an organism, to diagnostically monitor protein levels in tissue in pharmacogenomic analysis, for tissue typing, forensic identification, inhibiting protein function and to block ligand binding. (II) is useful as hybridization probes for cDNA and genomic DNA to isolate a full-length cDNA and genomic clones encoding (I), as primers for polymerase chain reaction (PCR) to amplify any given region of the polynucleotide, for expressing antigenic peptides, as probes for determining the chromosomal positions of the polynucleotides, for designing ribozymes, constructing host cells, transgenic animals and for identifying a disease or disorder associated with aberrant expression or activity of (II). Fragments of (II) are also useful to synthesize antisense molecules of desired length and sequences. (II) is also useful to detect mutations in genes and gene expression products such as mRNA, as antisense constructs to control gene expression and for chromosome identification. (III) is useful for producing proteins and polypeptides, for conducting cell-based assays involving the protein or fragments and to produce non-human transgenic animals which are useful for studying the function of a receptor protein and identifying and evaluating modulators of the protein activity.

☐ 38. Document ID: US 6331614 B1

L2: Entry 38 of 40 File: DWPI Dec 18, 2001

DERWENT-ACC-NO: 2002-129551
DERWENT-WEEK: 200217

TITLE: Nucleic acid encoding mutated form of human dual-specificity phosphatase CDC14A polypeptide, useful to diagnose and treat cancers

INVENTOR: TAVTIGIAN, S V; TENG, D H F ; WONG, A K C

PRIORITY-DATA: 1998US-113833P (December 23, 1998), 1999US-0468872 (December 22, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6331614 B1	December 18, 2001		022	C07H021/04

INT-CL (IPC): C07 H 21/02; C07 H 21/04; C12 N 15/00; C12 N 15/09; C12 N 15/63

ABSTRACTED-PUB-NO: US 6331614B
BASIC-ABSTRACT:

NOVELTY - An isolated nucleic acid (N1) encoding a CDC14A polypeptide (P1) with a fully defined sequence (S1) of 594 amino acids as given in the specification comprising a fully defined sequence (S2) of 1785 nucleotides as given in the specification, the complement of S2 or an RNA molecule corresponding to S2, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an expression vector comprising N1 operably linked to a promoter that directs expression of the nucleic acid;

(2) a vector (V1) which comprises N1;

(3) a host cell (H1) transformed in vitro with V1; and

(4) producing P1 comprising culturing H1 under conditions suitable for production of P1

and recovering P1.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Gene therapy; protein replacement therapy; protein mimetics. No supporting data is given.

USE - N1 and P1 are useful to diagnose and treat human cancers which have a mutation in the CDC14A gene, by gene therapy, protein replacement therapy or protein mimetics. They can also be used to screen for drugs to treat cancer.

☐ 39. Document ID: WO 200173060 A2 AU 200147782 A

L2: Entry 39 of 40 File: DWPI Oct 4, 2001

DERWENT-ACC-NO: 2001-616517
DERWENT-WEEK: 200261

TITLE: New polypeptide for modulating peptide activity and preventing hematopoietic disorders comprises the human dual specificity phosphatase 18221 protein

INVENTOR: MEYERS, R A

PRIORITY-DATA: 2000US-191858P (March 24, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200173060 A2	October 4, 2001	E	138	C12N015/55
AU 200147782 A	October 8, 2001		000	C12N015/55

INT-CL (IPC): A61 K 31/7088; A61 K 39/395; C07 K 16/40; C12 N 5/10; C12 N 9/16; C12 N 15/55; C12 Q 1/42; C12 Q 1/68; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200173060A
BASIC-ABSTRACT:

NOVELTY - An isolated nucleic acid molecule (I) encoding the human dual specificity phosphatase 18221 protein, is new.

DETAILED DESCRIPTION - An isolated nucleic acid (I) comprises:

(i) a nucleic acid molecule comprising a nucleotide sequence at least 80% homologous to a fully defined 1292 (S1) or 654 (S2) nucleotides, or the cDNA insert of a plasmid (II) deposited with the American Type Culture Collection (Accession number pending);

(ii) a nucleic acid molecule comprising a fragment of at least 462 nucleotides of (S1) or (S2), or a fragment of (II);

(iii) a nucleic acid molecule encoding a polypeptide (III) comprising a fully defined sequence of 218 amino acids, or the amino acid sequence encoded by (II);

(iv) a nucleic acid molecule encoding a fragment of (III), or a fragment of the amino acid sequence encoded by (II), where the fragment is at least 15 contiguous amino acids; and

(v) a nucleic acid molecule encoding a naturally allelic variant of (III), or the amino acid encoded by (II), where the nucleic acid molecule hybridizes to (S1) or (S2), or a complement, under stringent conditions.

INDEPENDENT CLAIMS are also included for the following:

(1) a host cell comprising (I);

(2) an isolated polypeptide (III) selected from the following:

(i) a polypeptide encoded by a nucleic acid molecule at least 80% homologous to (S1) or (S2), or (II);

(ii) a naturally occurring allelic variant of (III), or the amino acid encoded by (II), where the polypeptide is encoded by (I), or its complement, under stringent conditions; and

(iii) a fragment of at least 15 contiguous amino acids, of (III) or a polypeptide encoded by (II);

(3) an antibody which selectively binds to (III);

(4) producing (III), comprising culturing the host cell under conditions suitable for the expression of (I);

(5) detecting (III) in a sample comprising contacting the sample with a compound that selectively binds to (III) and determining the binding;

(6) a kit comprising a compound that selectively binds to (III), and instructions for use;

(7) detecting the presence of (I) comprising contacting the sample with a nucleic acid probe or primer that selectively hybridizes to (I), and determining any binding;

(8) detecting a compound that binds to (III), comprising contacting (III) or a cell expressing (III) with a test compound, and determining whether (III) binds to the test compound;

(9) modulating (III) activity, comprising contacting (III) or a cell expressing (III) with a compound in order to modulate the activity of (III);

(10) evaluating the efficacy of a treatment of a hematopoietic disorder in a subject, comprising:

(i) treating a subject with a protocol under evaluation;

(ii) assessing the expression level of a nucleic acid after the treatment, relative to the level prior to treatment; and

(11) diagnosing or staging a hematopoietic disorder in a subject.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Dual specificity phosphatase activity.

No biological data was provided.

USE - The polypeptides and polynucleotides are useful therapeutically to treat disorders characterized by insufficient or aberrant 18221 protein production. They can be used to evaluate the efficacy of treatment of hematopoietic disorders, especially erythroid-associated disorders (claimed), and to diagnose or stage hematopoietic disorders by detecting changes in expression relative to normal subjects. The polypeptides are useful to identify compounds binding to (claimed) and/or increasing/decreasing polypeptide activity (claimed), useful therapeutically, especially to treat or prevent hematopoietic disorders (claimed). For example, a compound modulating polypeptide activity/expression (e.g. a peptide; claimed) could be used to modulate hematopoiesis, especially in vivo in humans (claimed), by contacting a hematopoietic cell (e.g. an erythroid progenitor or differentiated cell; claimed), with the compound to alter cell proliferation, differentiation or survival (claimed). Such compounds are useful to treat conditions which involve increased hematopoietic cell activity or proliferation e.g. leukemias or decreased hematopoietic cell differentiation e.g. anemias, or to treat cancers e.g. renal carcinoma. The polypeptides can also be used to produce compounds selectively binding the polypeptide (especially antibodies), useful to detect the polypeptides (claimed) e.g. for disease

diagnosis; kits are provided (claimed). The polynucleotides can also be used to identify compounds modulating polynucleotide activity/expression (e.g. antisense molecules; claimed), useful to modulate hematopoiesis by contacting with a hematopoietic cell as above (claimed). The polynucleotides can also be used to produce nucleic acid probes/primers selectively hybridizing to the polynucleotides (e.g. nucleic acid probes hybridizing to mRNA molecules; claimed), useful to detect the polynucleotides (claimed) e.g. in disease diagnosis; kits are provided (claimed).

☐ 40. Document ID: WO 200039277 A2 AU 200023817 A

L2: Entry 40 of 40 File: DWPI Jul 6, 2000

DERWENT-ACC-NO: 2000-452383
DERWENT-WEEK: 200050

TITLE: New isolated nucleic acid molecules encoding human nuclear dual specificity phosphatase-like protein for diagnosis of androgen independent prostate cancers

INVENTOR: RICHARDSON, J; SHYJAN, A W ; VASSILIADIS, J

PRIORITY-DATA: 1998US-0223626 (December 29, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200039277 A2	July 6, 2000	E	108	C12N000/00
AU 200023817 A	July 31, 2000		000	C12N000/00

INT-CL (IPC): C12 N 0/00

ABSTRACTED-PUB-NO: WO 200039277A
BASIC-ABSTRACT:

NOVELTY - Isolated nucleic acid molecules (I) comprise the 2860 base pair (bp) or the 2436 bp sequence provided in the specification encoding human nuclear dual specificity phosphatase-like protein (NDSP) or the nucleic acid molecule which encodes the 812 amino acid sequence provided in the specification.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a host cell containing (I);

(2) an isolated polypeptide (II) comprising;

(a) a fragment of the 812 amino acid sequence provided in the specification, where the fragment comprises at least 15 contiguous amino acids; or

(b) a naturally occurring allelic variant of the 812 amino acid sequence provided in the specification, where the polypeptide is encoded by a nucleic acid comprising a sequence at least 55 % identical to the 2436 bp sequence provided in the specification;

(3) an antibody which selectively binds to (II);

(4) producing (II);

(5) a method (M1) for detecting the presence of (II);

(6) a kit comprising a compound which selectively binds to (II) or selectively hybridizes (I);

(7) a method (M2) for detecting the presence of (I);

(8) modulating the activity of (II) comprising contacting (II) or a cell expressing (II) with a compound which binds to the polypeptide;

(9) identifying a compound which modulates the activity of (II);

(10) a method (M3) for identifying a compound useful for treating prostate cancer comprising;

(a) measuring the expression level of NDSP in a biological sample comprising an androgen independent prostate cancer cell; and

(b) comparing the expression of NDSP in the presence and absence of the compound, where the compound is useful for treating prostate cancer when the expression level of NDSP in the presence of the compound is less than its expression level in the absence of the compound;

(11) determining if a prostate cancer in a patient not undergoing androgen withdrawal therapy is androgen dependent comprising;

(a) providing a sample of patient prostate cancer cells; and

(b) determining if NDSP is expressed in the sample of prostate cancer cells, where the absence of NDSP expression indicates that the prostate cancer is androgen independent; and

(12) determining the efficacy of androgen withdrawal treatment in a prostate cancer patient comprising;

(a) providing a biological sample from the patient from a first time point and determining the expression level of NDSP;

(b) providing a biological sample from the patient at a second time point, occurring after the patient has begun androgen withdrawal treatment and determining the expression level of NDSP; and

(c) comparing the expression levels of NDSP in the first and second samples, where an increase in the expression level in the second sample compared with the first sample indicates that the androgen withdrawal treatment has become less effective.

USE - (I) and (II) can be used to detect androgen independent prostate cancers.

ADVANTAGE - Androgen independent prostate cancers can be distinguished from androgen dependent prostate cancers and a more suitable treatment regime can be implemented. Current treatment for prostate cancers involve androgen withdrawal, which is an ineffective treatment for androgen independent prostate cancer.

Terms	Documents
dual specificity phosphatase same humen and (nucleic acid or gene or dna or cdna)	40

Previous Page Next Page